Development of agents for controlling mood

情绪控制剂的开发

• 批准号: 7599893
• 负责人: Sergei Merkulov
• 金额: $ 25万
• 依托单位: LUCCELL, INC.
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-04-03 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7599893
• 关键词: Adverse effects; Aggressive behavior; Animals; Anxiety; Anxiety Disorders; Arrhythmia; Behavior; Behavior Therapy; Biomedical Research; Brain; Brain Diseases; Breathing; Cell physiology; Cells; Code; Communities; Coupled; Desire for food; Development; Disease; Dorsal; Drug Controls; ETS Domain; Emotions; Endocrine; Enhancers; Enterochromaffin Cells; Exposure to; Functional disorder; G-Protein Signaling Pathway; GTP-Binding Proteins; Gastrointestinal tract structure; Gated Ion Channel; Genes; Genomics; Goals; Halorhodopsins; Human; Imaging Techniques; In Vitro; Infection; Ions; Irritable Bowel Syndrome; Light; Marketing; Medical Research; Membrane Potentials; Mental disorders; Methods; Moods; Mus; Muscle; Mutation; Names; Nature; Neurons; Neurotransmitters; Normal Cell; Organ; Parkinson Disease; Pathway interactions; Pattern; Pharmaceutical Preparations; Pharmacologic Substance; Physiological; Physiology; Principal Investigator; Property; Proteins; Regulation; Regulatory Element; Reporter Genes; Research; Research Personnel; Rest; Rhodopsin; Role; Schizophrenia; Serotonin; Serotonin Agents; Signal Transduction; Sleep; Source; Spinal Cord; Subfamily lentivirinae; System; Technology; Viral; Virus; base; behavior influence; body system; cell type; depression; design; feeding; in vivo; innovative technologies; light gated; mature animal; mind control; molecular imaging; neuronal excitability; novel strategies; presynaptic; programs; promoter; protein expression; public health relevance; research and development; research study; response; tool; transcription factor; transgene expression

DESCRIPTION (provided by applicant): LucCell, Inc. is a medical and research development company whose goal is to develop innovative technology for the research community as well as potential treatments for psychiatric diseases. LucCell's innovative technology combines viral delivery methods with light activated proteins and cell-type specific genomic information to control brain circuitry and cellular signaling. LucCell's unique advantage will be the ability to validate these tools using sophisticated physiological, molecular, and imaging techniques. We will create viruses that contain cell-type specific promoters/enhancers in combination with light activated proteins for cell-type specific expression of the light activated protein of choice. Our initial effort will be aimed at controlling presynaptic serotonergic circuitry in the brain. This allows us to switch on or off serotonin neurons precisely, quickly and controllably by exposure to light. This approach was recently named a "Method to Watch" in a feature called "Method of the Year" (Nature Methods 5, 23 (2008)). Using this approach we will be able to produce research tools that will enable researchers to enhance their understanding of cellular function, particularly in neuronal circuits. The unique LucCell products are not available from any other source. PUBLIC HEALTH RELEVANCE: The LucCell products will enable researchers to enhance their understanding of cellular function, particularly in neuronal circuits, and second will enable clinicians to control serotonin levels in humans. Drugs controlling serotonin levels in the brain are currently the main medications in anxiety disorders, schizophrenia and depression. These drugs are frequently ineffective or carry a considerable side-effect burden. Thus, LucCell's technology promises a wholly novel approach to treatment of these diseases.

描述（由申请人提供）：LucCell, Inc.是一家医疗和研究开发公司，其目标是为研究界开发创新技术以及潜在的精神疾病治疗方法。LucCell的创新技术将病毒传递方法与光激活蛋白和细胞类型特定的基因组信息相结合，以控制大脑回路和细胞信号。LucCell的独特优势将是能够使用复杂的生理、分子和成像技术验证这些工具。我们将创建包含细胞类型特异性启动子/增强子与光激活蛋白结合的病毒，用于选择光激活蛋白的细胞类型特异性表达。我们最初的目标是控制大脑突触前的血清素能回路。这使我们能够通过光照精确、快速、可控地打开或关闭血清素神经元。这种方法最近在一篇名为“年度方法”的专题中被命名为“值得关注的方法”（Nature Methods 5, 23(2008)）。使用这种方法，我们将能够生产研究工具，使研究人员能够提高他们对细胞功能的理解，特别是在神经元回路中。独特的LucCell产品无法从任何其他来源获得。公共卫生相关性：LucCell产品将使研究人员能够加强他们对细胞功能的理解，特别是在神经回路中，其次将使临床医生能够控制人体血清素水平。控制大脑中血清素水平的药物目前是治疗焦虑症、精神分裂症和抑郁症的主要药物。这些药物通常无效或有相当大的副作用。因此，LucCell的技术有望为治疗这些疾病提供一种全新的方法。